ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,066.00
-0.07%
Dow Jones
40,003.59
0.34%
Brent Oil
83.76
0.00%
Bitcoin
66,874.90
-0.31%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Oric Pharmaceuticals Inc (ORIC) Quote

Oric Pharmaceuticals Inc

Oric Pharmaceuticals Inc (ORIC)

NASDAQ
9.16
0.14
(1.55%)
Closed May 17 4:00PM
Delayed by 15 minutes
9.16
0.00
(0.00%)
After Hours: 7:27PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
9.16
Bid
8.96
Ask
9.65
Volume
368,164
8.69 Day's Range 9.30
4.91 52 Week Range 16.65
Market Cap
614.468M
Previous Close
9.02
Open
8.99
Last Trade
5
@
9.65
Last Trade Time
Financial Volume
$ 3,351,603
VWAP
9.1036
Average Volume (3m)
574,651
Shares Outstanding
67,375,847
Dividend Yield
-
PE Ratio
-6.10
Earnings Per Share (EPS)
-1.49
Revenue
-
Net Profit
-100.7M

About Oric Pharmaceuticals Inc

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company h... ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.oricpharma.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Oric Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ORIC. The last closing price for Oric Pharmaceuticals was $9.02. Over the last year, Oric Pharmaceuticals shares have traded in a share price range of $ 4.91 to $ 16.65.

Oric Pharmaceuticals currently has 67,375,847 shares outstanding. The market capitalization of Oric Pharmaceuticals is $614.47 million. Oric Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.10.

ORIC Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 06 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 06 2024
Edgar (US Regulatory)

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first...

May 06 2024
GlobeNewswire Inc.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO and SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...

May 03 2024
GlobeNewswire Inc.

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an...

April 15 2024
GlobeNewswire Inc.

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus...

April 08 2024
GlobeNewswire Inc.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...

April 05 2024
GlobeNewswire Inc.

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

April 04 2024
GlobeNewswire Inc.

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

March 11 2024
Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

March 11 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.71-7.193515704159.879.878.693180219.0886894CS
4-0.21-2.241195304169.3710.157.624209988.94756912CS
12-1.27-12.176414189810.4316.657.6257465112.10902708CS
262.5237.95180722896.6416.656.5748653811.04306696CS
524.1382.10735586485.0316.654.914574389.11252355CS
156-15.94-63.505976095625.126.72.363944238.30290151CS
260-16.84-64.76923076922640.812.3635265311.99852623CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DUOFangDD Network Group Ltd
$ 1.65
(313.74%)
104.67M
FLJFLJ Group Limited
$ 1.54
(220.90%)
57.28M
JFBRJeffs Brands Ltd
$ 0.6276
(102.45%)
37.97M
IPWiPower Inc
$ 2.89
(97.95%)
11.05M
CETXCemtrex Inc
$ 0.4851
(48.58%)
21.22M
BSFCBlue Star Foods Corporation
$ 0.0757
(-45.26%)
60.09M
SINTSiNtx Technologies Inc
$ 0.084602
(-39.57%)
156.33M
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
HSCSHeart Test Laboratories Inc
$ 7.00
(-38.11%)
348.9k
AMPGAmplitech Group Inc
$ 1.46
(-32.09%)
613.31k
CRKNCrown Electrokinetics Corporation
$ 0.171
(-28.75%)
1.73B
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
GWAVGreenwave Technology Solutions Inc
$ 0.1541
(4.05%)
1.16B
AKANAkanda Corporation
$ 0.1726
(30.26%)
566.3M
PEGYPineapple Energy Inc
$ 0.1053
(-28.85%)
219.2M

ORIC Discussion

View Posts
Monksdream Monksdream 2 weeks ago
ORIC 10Q due 5/6
👍️0
Monksdream Monksdream 2 weeks ago
ORIC under $10
👍️0
Monksdream Monksdream 2 months ago
ORIC 10Q due 3/16
👍️0
Monksdream Monksdream 2 months ago
ORIC new 52 week high
👍️0
Monksdream Monksdream 2 months ago
ORIC new 52 week high
👍️0
Monksdream Monksdream 3 months ago
ORIC new 52 week high
👍️0
Monksdream Monksdream 3 months ago
ORIC new 52 weewk high
👍️0
Monksdream Monksdream 4 months ago
ORIC new 52 week high
👍️0
TheFinalCD TheFinalCD 1 year ago
$ORIC LOOKS LIKE $6 COMING
👍️0
makinezmoney makinezmoney 1 year ago
$ORIC: Tapped $5.40....... still got steam

It ain't over yet





GO $ORIC
👍️0
DH112 DH112 1 year ago
Today is green fields
👍️0
TheFinalCD TheFinalCD 1 year ago
Pfizer will pay $4.65 per share for 5,376,344 of Oric's common shares, for a total of $25 million. The companies plan to move the treatment into a Phase 2 clinical trial in combination with elranatamab, Pfizer's investigational treatment of multiple myeloma

https://finance.yahoo.com/news/oric-pharmaceuticals-announces-clinical-development-224800151.html
👍️0
makinezmoney makinezmoney 1 year ago
$ORIC: 5.25 now........................... lets get to $10

I know you can do it babyyyyyyyyyyyyyyyyy


GO $ORIC
👍️0
makinezmoney makinezmoney 1 year ago
$ORIC : Now at 4.90

YESsssssssssssssss............ this is very impressive news with deal with Pfizer.

Me likes it


GO $ORIC
👍️0
crudeoil24 crudeoil24 1 year ago
Shares of Oric Pharmaceuticals Inc. jumped nearly 60% to $4.79 in premarket trading Thursday after the company agreed to sell $25 million in shares to Pfizer Inc.

The clinical-stage oncology company said Wednesday evening that Pfizer has agreed to buy nearly 5.4 million shares of Oric's common stock for $4.65 apiece.

The investment is part of a clinical development collaboration between the two companies on a Phase 2 study examining Oric's ORIC-533 treatment for multiple myeloma, the companies said.

The companies said the collaboration would potentially advance the treatment into a combination study with Pfizer's elranatamab, an investigational treatment for multiple myeloma.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

December 22, 2022 07:25 ET (12:25 GMT)
👍️0
makinezmoney makinezmoney 1 year ago
$ORIC: BOOOoommmmmmm........... Pfiizer invests $25Milly in ORIC

Letssssssss goooooooooooooooooo.


Added 5k shares here at 4.30

Great NEWS


https://www.tipranks.com/news/oric-pharmaceuticals-nasdaqoric-stock-spikes-on-pfizer-deal

GO $ORIC
👍️0

Your Recent History

NASDAQ
ORIC
Oric Pharmaceuticals
KOSDAQ
096690
Aroot
BIT
COV
Cover 50
BIT
UV4KWR
UniCredit Bank
USOTC
TEXG
Terax Energy (CE)
LSE
12VG
Op Corp Bank 31
AMEX
SDP
ProShares UltraShort Uti...
COIN
SWZLUST
SwapZilla
COIN
PXLUSD
EU
JCQ
Jacquet Metals
ASE
G101221A2
Greece
BINA
OMBTC
MANTRA DAO
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved